MAP2K7 and cancer: These compounds were selected from two broad classes of anti-cancer drugs, referred to as epigenetic-modifying compounds and cell cycle inhibitors, which have been proposed to be used in combination with standard of care BRAF and MEK inhibitors to overcome drug-adapted subpopulations of cells in BRAF-mutant melanomas [10,21,41–49].